Jennifer Doudna and Emmanuelle Charpentier were awarded the Japan Prize today for their invention of the revolutionary gene-editing technology known as CRISPR-Cas9, which has swept into research labs around the world and is already yielding new therapies for cancer and hereditary diseases.
The University of California, Berkeley has joined forces with pharmaceutical giant Novartis to establish a new research collaboration aimed at unlocking difficult drug targets to accelerate the discovery of new medicines in areas such as infectious diseases and cancer.
The College of Chemistry is very pleased to announce that Dr. Paula Hammond, Head of the Department of Chemical Engineering at MIT, will present this year’s Dow Chemical lecture series on Chemical and Biomolecular Engineering at UC Berkeley. The lectures will be held on the Berkeley campus September 18th and 20th.
Newsweek spoke with Jennifer Doudna co-discover of the breakthrough gene-editing technique, about how quickly the technology is advancing and the progress she expects to see in the future.
Daniel Nomura and fellow researchers have found a long-elusive Achilles' heel within "triple-negative" breast tumors, a common type of breast cancer that is difficult to treat.
Jennifer Doudna and Emmanuelle Charpentier were awarded the Japan Prize today for their invention of the revolutionary gene-editing technology known as CRISPR-Cas9, which has swept into research labs around the world and is already yielding new therapies for cancer and hereditary diseases.
David Savage, assistant professor of chemistry, has won an NIH Director's New Innovator Award.
Ken Raymond, who, thanks to a new DOE grant and a successful startup, is finding his retirement busier than expected.
The University of California, Berkeley has joined forces with pharmaceutical giant Novartis to establish a new research collaboration aimed at unlocking difficult drug targets to accelerate the discovery of new medicines in areas such as infectious diseases and cancer.
The Verge talks with Jennifer Doudna to discuss just what CRISPR might mean for the future of science, and disease research.
Daniel Nomura and fellow researchers have found a long-elusive Achilles' heel within "triple-negative" breast tumors, a common type of breast cancer that is difficult to treat.
Evan Miller discusses how